

**510(k) Summary***K011970***1) Submitter's Name  
Address, contact**

BIOSAFE Laboratories, Inc.  
100 Field Drive, Suite 240  
Lake Forest, IL 60045

Phone: (847) 234-8111  
FAX: (847) 234-8222

Contact Person: Jack A. Maggiore, PhD  
BIOSAFE Laboratories, Inc.  
(773) 693-0400, x253

Date Prepared: August 22, 2001

**2) Device Name**

Proprietary Name: BIOSAFE CHOLESTEROL PROFILE  
Blood Collection and Transport System

Common Name: Capillary blood self-collection and  
transportation system for Total Cholesterol,  
HDL Cholesterol, Triglycerides and Calculated  
LDL Cholesterol

Classification Names: Cholesterol (21 CFR 862.1175)  
HDL Cholesterol (21 CFR 862.1475)  
Triglycerides (21 CFR 862.1705)  
LDL Cholesterol (21 CFR 862.1475)

**3) Predicate Devices**

Total Cholesterol	Beckman Synchron Synchron CX Systems Cholesterol (CHOL) Reagent (K974046)
HDL Cholesterol	Sigma EZ HDL™ Cholesterol Reagent (K972041)
Triglycerides	Beckman Triglycerides Reagent Kit (K781939)

**4) Device Description**

The device is a kit containing the materials necessary to collect a capillary blood sample onto a filter paper card for transport to a certified clinical laboratory for lipid profile testing. The kit is comprised of a blood collection card packaged in a foil pouch, alcohol prep pad, disposable lancets, gauze pad, bandage strip, collection instructions, return prepaid envelope, and a patient test authorization form.

**5) Intended Use**

The BIOSAFE CHOLESTEROL PROFILE Blood Collection and Transport System is intended for prescription distribution, and is a clinic-use device for collection and transportation of dried capillary blood for *in vitro* diagnostic quantitative determination of Total Cholesterol, HDL-Cholesterol, Triglycerides and Calculated LDL-Cholesterol in dried blood spots. This kit is not intended for use on neonates. LDL cannot be determined where the triglyceride value is greater than 400 mg/dL

*Continued on next page*

## 510(k) Summary, *continued*

---

6) Comparison to predicate device

The BIOSAFE CHOLESTEROL PROFILE Blood Collection and Transport System has technological characteristics and an intended use that are substantially equivalent to that of the predicate devices listed above. The BIOSAFE CHOLESTEROL PROFILE Blood Collection and Transport System provides components that permit collection, storage, and transportation of a dried capillary blood sample to a certified clinical laboratory for analysis using FDA-Cleared laboratory reagent and analysis systems. All predicate and current kits are intended for the *in vitro* diagnostic laboratory determination of lipid profile analytes. The laboratory analyses used in conjunction with the BIOSAFE CHOLESTEROL PROFILE Blood Collection and Transport System, utilize the Synermed Cholesterol Reagent Kit (K903015), Sigma Diagnostics Infinity Triglyceride Reagents (K844032), and Sigma Diagnostics EZ-HDL Cholesterol Reagents (K972041). Results of clinical trials show that professionally collected capillary samples onto the BIOSAFE Blood Collection Card provide results that are substantially equivalent to venous (serum) results for Total Cholesterol, HDL Cholesterol and Triglycerides when analyzed using BIOSAFE Laboratories modified analytical methods.

---

7) Performance Studies

Determination of professionally collected capillary blood Total Cholesterol, HDL Cholesterol and Triglycerides using the BIOSAFE CHOLESTEROL PROFILE Blood Collection and Transport System is substantially equivalent to venous (serum) samples for lipid profile testing BIOSAFE Laboratories modified analytical methods. Performance studies were conducted on professionally collected blood samples from volunteer study subjects at three different geographical sites. A corresponding venous blood sample was collected by the health care professional in order to compare serum lipid results to those obtained from capillary blood samples collected onto the BIOSAFE Blood Collection Card. Venous samples were express shipped, and dried capillary samples were mailed directly to BIOSAFE Laboratories for lipid profile analysis by their respective methods.

---

8) Test Summary

Performance characteristics studied included precision, linearity and correlation. In addition, the BIOSAFE CHOLESTEROL PROFILE Blood Collection and Transport System was evaluated for sample stability when exposed to abusive storage and transportation conditions.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Jack A. Maggiore, Ph.D.  
Director, Clinical Trials  
BIOSAFE Laboratories, Inc.  
100 Field Drive – Suite 240  
Lake Forest, IL 60045

SEP 26 2001

Re: k011970  
Trade/Device Name: BIOSAFE Cholesterol Profile Blood Collection--  
and Transport System  
Regulation Number: 21 CFR 862.1675  
Regulation Name: Blood specimen collection device  
Regulatory Class: Class II  
Product Code: JKA  
Regulatory Class: Class I, reserved  
Product Code: CHH, LBS, CDT  
Dated: August 23, 2001  
Received: September 4, 2001

Dear Dr. Maggiore:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory-Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

K011970

C-1

### C. Indications for Use Statement

The BIOSAFE CHOLESTEROL PROFILE Blood Collection and Transport System is intended for prescription distribution, and is a clinic-use device for collection and transportation of dried capillary blood for *in vitro* diagnostic quantitative determination of Total Cholesterol, HDL-Cholesterol, Triglycerides and Calculated LDL-Cholesterol in dried blood spots. This kit is not intended for use on neonates. LDL cannot be determined where the triglyceride value is greater than 400 mg/dL.

✓ prescription use

Kesia Alexander for Juan Cooper

(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number K011970